Compare TG Therapeutics Inc (TGTX) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs United States Natural Gas Fund — how do they compare? TG Therapeutics Inc trades at $49.44 (market cap $7.64B), while United States Natural Gas Fund trades at $10.18. The key difference: TG Therapeutics Inc is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals.
| TGTX | UNG | |
|---|---|---|
Market Cap | $7.64B | — |
Sector | Health | Commodities - Energy |
52-Week High | $59.06 | $16.90 |
52-Week Low | $26.94 | $9.63 |
Enterprise Value | $7.84B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
UNG trades at $10.20, up 0.59% with a bearish technical signal from moving averages. The ETF shows neutral momentum oscillators with mixed directional indicators. Recent news highlights natural gas price stability amid weather-driven demand fluctuations and ongoing discussions about futures versus equity exposure in the natural gas sector.
The outlook remains cautious with technical weakness offset by fundamental supply-demand dynamics. Investment opportunities exist in potential weather-driven price spikes, while risks include commodity volatility and the structural challenges of futures-based ETFs tracking spot prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
